Abstract: The development of new treatment options has dramatically improved the landscape for patients with advanced melanoma. Part of these advances emerged through the identification of the importance of factors that regulate the immune system, including proteins that negatively modulate T cell-mediated responses termed "immune checkpoints." Indeed, blockade of the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint served as a proof of principle that the manipulation of these molecules could induce robust anticancer effects, yet limited to a small percentage of patients. Targeting a distinct checkpoint, the PD-1 yielded improved outcomes and reduced toxicity compared with CTLA-4 blockade and, in separate studies, chemotherapy. More recently, combined CTLA-4/PD-1 blockade was shown to result in higher response rates, while accompanied by increased toxicity. In this article, we review the clinical development of anti-PD-1 monotherapy and combinations that may expand the benefit of immunotherapy for patients with advanced melanoma.
1
The recognition of aberrant activation of the mitogen-activated protein kinase pathway resulting in mutations of the V-Raf murine sarcoma viral oncogene homolog B (BRAF) gene paved the way for the development of highly active small molecules, 2, 3 resulting in the approval of the BRAF inhibitors vemurafenib and dabrafenib and the mitogen-activated protein kinases enzymes (MEK) inhibitors cobimetinib and trametinib for patients with tumors harboring oncogenic BRAF mutations. [3] [4] [5] Advances in the manipulation of the mitogen-activated protein kinase pathway have been mirrored by the development of monoclonal antibodies capable of improving an antitumor immune response by inhibiting negative modulators of the immune response or immune checkpoints. 6 Agents targeting the cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and PD-1 and its ligand PD-L1 have become important strategies to control tumor growth in patients with advanced melanoma, with now impressive survival gains (Fig. 1) . In 2011, ipilimumab, a fully human monoclonal antibody against CTLA-4, became the first agent of its class approved for clinical use for patients with advanced melanoma. The approval was based on survival gains in randomized phase III clinical trials 7, 8 and provided a new therapy for patients that led to a solid possibility of prolonged antitumor immunity and sustained disease control. 9, 10 Although CTLA-4 was the first immune checkpoint to demonstrate clinical success, other investigations have explored a wide variety of cell-surface receptors distinct from CTLA-4 that are also involved in the modulation of immune responses, including the immune-agonist receptors CD28, OX40, CD27, CD137, HVEM, and GITR and the inhibitory coreceptors (or other checkpoints) PD-1, VISTA, BTLA, TIM-3, and LAG-3.
11,12 Among these newer targets, blockade of PD-1 or its ligand, PD-L1, has been more extensively studied.
Preclinical studies first shed light on the relevance of the PD-1 and PD-L1 in regulating immune responses. Mice lacking PD-1 were shown to develop autoimmune manifestations, including lupus-like arthritis, glomerulonephritis, autoimmune cardiomyopathy, and graft-versus-host-like disease, highlighting the role of the PD-1/PD-L1 and PD-L2 axis in the maintenance of tolerance and down-regulation of immune responses. 13, 14 The interaction of PD-1 and its ligands PD-L1 and PD-L2 was subsequently confirmed as an inhibitory pathway involved in the negative regulation of peripheral T-cell activity and related to evasion mechanisms by tumor cells, 15, 16 proposing a potential target for drug development. Indeed, robust and durable tumor regressions have been demonstrated in clinical trials investigating the antitumor effects of anti-PD-1 agents. Currently, the fully human IgG4 monoclonal antibody nivolumab and the humanized IgG4 antibody pembrolizumab are approved for clinical use and among the standard first-line treatment options for patients with advanced melanoma. 1 More recently, an enhanced antitumor effect was demonstrated with the concurrent use of ipilimumab and nivolumab, and a growing number of other combinations are being investigated. 17, 18 In this article, we review the results of clinical trials that support the use of nivolumab, pembrolizumab, and combined checkpoint blockade in clinical practice for patients with advanced melanoma and address open questions related to the clinical use of these agents.
Early-Phase Clinical Trials Investigating
Single-Agent Anti-PD-1 Therapy
The development of anti-PD-1 agents in melanoma prompted significant enthusiasm since early-phase clinical trials. In a dose-escalation, phase I study (CA209-003), nivolumab was evaluated at doses ranging from 0.1 to 10 mg/kg of body weight every 2 weeks in 296 patients with a variety of solid tumors, including advanced melanoma, non-small cell lung cancer, prostate cancer, renal cell carcinoma, and colorectal cancer. Of note, no maximum tolerated dose was achieved, and nivolumab demonstrated a favorable toxicity profile, with an incidence of grade 3 or 4 treatment-related adverse events of 14%. Activity was demonstrated across all doses; objective responses occurred in an impressive 26 of 94 evaluable patients with melanoma (28%). 19 Results of 107 patients with melanoma treated with nivolumab in this phase I study were subsequently updated in 2014: median overall survival (OS) was 16.8 months (95% confidence interval [CI], 12.5-31.6 months), with a 2-year OS rate of 43%. It is important to highlight that 62% of these patients had received 2 to 5 prior systemic therapies before enrolling onto this phase I trial. Objective responses were seen in 31% of patients, and in line with prior observations with ipilimumab, responses were durable. 20 Five-year OS analyses were presented in 2016, confirming the possibility of sustained disease control with PD-1 blockade, with 34% of the melanoma patients alive at 5 years. 21 Similarly, pembrolizumab demonstrated significant antitumor effect and good tolerability in a large-scale, phase I study (KEYNOTE-001) that included 655 patients divided across multiple cohorts and enrolled between December 2011 and September 2013. 22 Pembrolizumab was administered intravenously at 2 to 10 mg/kg every 2 weeks and every 3 weeks. A comprehensive analysis including the 8 study cohorts was published after a median follow-up of 21 months. 23 Once again, single-agent anti-PD-1 therapy was shown to be well tolerated: 14% of the patients experienced a grade 3 or 4 treatment-related adverse event. Objective response rate (ORR) across all cohorts and doses was 33%, and it was 45% in treatment-naive patients. Of note, 74% (152/205) of responses were ongoing at the time of data cutoff. Median OS in the total population was 23 months (95% CI, 20-29 months), with a 2-year OS rate of 49%. Median OS was 31 months in treatmentnaive patients (95% CI, 24 months to not reached). Three-year OS analyses of KEYNOTE-001 24 were presented in 2016: whereas the duration of response had not been reached, median OS was 24.4 months in the general population and 32.2 months in treatmentnaive patients.
The spectrum of toxicity of both nivolumab and pembrolizumab in early-phase clinical trials is, as expected, largely attributable to immune-related events, and the most frequent any-grade adverse events were fatigue, rash and/or pruritus, diarrhea, and thyroiditis/hypothyroidism. 25 Nevertheless, virtually any organ or tissue may be affected by excessive immunity in the setting of PD-1 blockade, and serious, yet uncommon adverse events include pneumonitis, nephritis, hypophysitis, adrenalitis, myocarditis, hematologic disorders (e.g., immune-mediated hemolytic anemia), and neurologic events (e.g., Guillain-Barré syndrome, myasthenic syndromes, and meningitis/meningoencephalitis). Other laboratory abnormalities can occur, including elevation of aspartate aminotransferase and/or alanine aminotransferase (although severe hepatitis and liver failure are rare), as well as elevations in amylase and lipase. It is important to highlight that it is possible that late toxicities may ensue after a long duration of treatment, but it does not appear that toxicities are cumulative as treatment duration continues. 20 Efficacy of Single-Agent Anti-PD-1 Agents Versus Standard Therapies in Ipilimumab-Refractory
Patients in Randomized Trials
Because of unprecedented antitumor activity resulting from anti-PD-1 immunotherapy in early-phase clinical studies, randomized registration trials of nivolumab and pembrolizumab were rapidly conducted in order to assess the efficacy and tolerability of these agents initially in ipilimumab-(and BRAF inhibitor-) refractory patients.
In the CheckMate-037 trial, patients with advanced melanoma who progressed after ipilimumab (and a BRAF inhibitor for those with a BRAF V600 mutation) were randomly assigned 2:1 to nivolumab 3 mg/kg administered every 2 weeks (n = 272) or investigator's choice of chemotherapy (dacarbazine or carboplatin/ paclitaxel) (n = 133) between December 2012 and January 2014. 26 The primary endpoints were objective response rate and OS, and patients were stratified according to the presence or absence of a BRAF mutation, tumor expression of PD-L1, and previous response to ipilimumab. Among the 120 initial patients randomly allocated to nivolumab treatment, ORR was 31.7%, in comparison to 10.6% in the chemotherapy group. Results were updated after a median follow-up of approximately 2 years, including the 405 patients initially accrued. 27 Objective response rate (27% vs. 10%) and duration of response (32 vs. 13 months) were higher with nivolumab compared with chemotherapy. No statistically significant differences in OS were reported (median OS with nivolumab 15.7 vs. 14.4 months with chemotherapy; 95.54% CI, 0.73-1.24), with 2-year OS rates of 38.7% versus 33.9%. However, 41% of the patients initially treated with chemotherapy received an anti-PD-1 agent subsequently. 27 One additional factor that highlights the need for caution in the interpretation of OS results is the proportion of patients who did not receive the assigned treatment after randomization in this open-label study: 23% of the patients in the chemotherapy group versus 2% in the nivolumab group. In this updated analysis, treatment-related adverse events of any grade occurred in 77% and 82% of patients in the nivolumab and chemotherapy groups, respectively, and grades 3 and 4 adverse events in 14% and 34%, respectively; 51% of the patients in the nivolumab group received an immune-modulating agent for the treatment of toxicities, most frequently systemic corticosteroids. 27 Similarly, the KEYNOTE-002 randomized phase II trial investigated the efficacy of investigational regimens of pembrolizumab (2 or 10 mg/kg every 3 weeks), with chemotherapy (carboplatin and paclitaxel, carboplatin, paclitaxel, temozolomide, or dacarbazine) as the comparator arm. 28 The study primary endpoint was progressionfree survival (PFS) in the intention-to-treat population. Patients were required to have progressive disease following prior ipilimumab and, if BRAF V600 mutant, also BRAF and/or MEK inhibition, and were stratified by Eastern Cooperative Oncology Group performance status, lactate dehydrogenase concentration, and BRAF V600 mutation status. Between November 2012 and November 2013, 540 patients were enrolled and randomized. The use of pembrolizumab was associated with a statistically significant improvement in median PFS, with a 6-month PFS rate of 34% in the pembrolizumab 2-mg/kg arm, 38% in the pembrolizumab 10-mg/kg arm, and 16% in the chemotherapy group (P<0.0001 for the comparison of both arms vs. chemotherapy). Best ORRs were 21% and 25% for the 2-and 10-mg/kg arms, respectively, versus 4% in the control arm based on independent central review. The incidence of grades 3 and 4 treatment-related adverse events was 11% to 14% with pembrolizumab and 26% with chemotherapy. With extended follow-up, and replicating what was reported in CheckMate-037, no significant OS benefit was seen with the use of pembrolizumab, and 2-year OS rates were 35.9% and 38.2% in pembrolizumab 2-and 10-mg/kg arms, respectively, and 29.7% in the control arm, with 55% of the patients in the control arm crossing over to pembrolizumab. 29 
Efficacy of Single-Agent Anti-PD-1 Agents Versus Standard Therapies in Ipilimumab-Naive Patients in Randomized Trials
In ipilimumab-naive patients, both nivolumab and pembrolizumab resulted in superior OS and better tolerability when compared with ipilimumab or chemotherapy. In the CheckMate-066 phase III trial, 418 untreated patients without a BRAF mutation were randomized in the frontline setting to receive nivolumab at the standard dose of 3 mg/kg every 2 weeks or dacarbazine. 30 Randomization was stratified according to PD-L1 expression status (positive vs. negative or indeterminate) and metastasis stage defined according to the staging system of the American Joint Committee on Cancer. Overall survival rate at 1 year was 72.9% for nivolumab and 42.1% for dacarbazine (hazard ratio [HR], 0.42; 99.79% CI, 0.25-0.73; P < 0.001), with objective responses occurring in 40% (including 7.6% of complete responses) and 13.9% of the patients in each arm, respectively (odds ratio, 4.06; P < 0.001). Median PFS was also significantly prolonged with nivolumab (median PFS, 5.1 vs. 2.2 months; HR, 0.43; 95% CI, 0.34-0.56; P < 0.001). The incidence of treatment-related grade 3 or 4 adverse events was 11.7% among those treated with nivolumab. 30 Long-term data subsequently presented suggested a 2-year OS rate of 57.7% with nivolumab (median OS not reached) and 26.7% with chemotherapy (HR, 0.43; 95% CI, 0.33-0.57; P < 0.001). 31 In the first-line setting, nivolumab also compared favorably with ipilimumab in the randomized CheckMate-067 trial, which also comprised a third arm consisting of combined ipilimumab and nivolumab and is discussed in more detail below ("Anti-PD-1-and Anti-CTLA-4-Based Combinations"). 18 Pembrolizumab was also investigated in immunotherapynaive patients in the phase III KEYNOTE-006 trial, which randomized 834 patients between September 2013 and March 2014 into 3 treatment arms: pembrolizumab 10 mg/kg every 2 weeks or every 3 weeks, or ipilimumab 3 mg/kg every 3 weeks for 4 doses. 32 Patients were stratified based on Eastern Cooperative Oncology Group performance status, line of therapy, and PD-L1 expression, and the primary endpoint was OS. In the final OS analysis after a median follow-up of 22.9 months, pembrolizumab resulted in a significant improvement in 2-year OS rates when compared with ipilimumab (55% in both pembrolizumab arms vs. 43%; HR, 0.68 [95% CI, 0.53-0.87; P = 0.0009] and 0.68 [95% CI, 0.53-0.87; P = 0.0008], for 2-and 3-week schedules compared with ipilimumab, respectively). 33 In a recent update of this study, with additional 11 months of follow-up (33.9 months of median follow-up in total), median OS in pembrolizumab arms was 32.3 months, and it was 15.9 months in the ipilimumab group (HR, 0.70; 95% CI, 0.58-0.86), with revised best ORR of 42% versus 16%; the median duration of response had not been reached in patients treated with pembrolizumab. 34 There seemed to be no significant differences between administering pembrolizumab every 2 or every 3 weeks.
Although these trials allowed subsequent therapies and, as discussed before, crossover to either subsequent anti-PD-1 or ipilimumab was significant, the only trial to specifically address sequencing of single-agent nivolumab or ipilimumab was the CheckMate-064 study. 35 In this randomized phase II trial, patients with advanced melanoma (treatment naive or with progression after no more than 1 previous systemic therapy) were randomly assigned to induction with either nivolumab 3 mg/kg every 2 weeks for 6 doses followed by ipilimumab 3 mg/kg every 3 weeks for 4 doses, or the reverse sequence. After induction, both arms received maintenance treatment with nivolumab 3 mg/kg every 2 weeks until disease progression. Upfront treatment with nivolumab followed by ipilimumab resulted in higher ORR at week 25 (41% vs. 20%) and prolonged OS when compared with ipilimumab followed by nivolumab (median OS not reached vs. 16.9 months; 12-month OS: 76% vs. 54%); of note, the incidence of grades 3 to 5 treatment-related adverse events was similar between groups (50% in the nivolumab followed by ipilimumab group vs. 43% among those treated with upfront ipilimumab). 35 
Anti-PD-1-and Anti-CTLA-4-Based Combinations
Based on the results of randomized trials, anti-PD-1 monotherapy rapidly was consolidated among the standard first-line therapies for patients with advanced melanoma (Table 1) . Nevertheless, many patients do not respond favorably to anti-PD-1. Based on preclinical models and the availability of clinical agents, the combination of anti-CTLA-4 and PD-1 agents emerged to potentially enhance the activity of immunotherapy.
In a phase I, dose-escalation study, the combination of nivolumab and ipilimumab was administered every 3 weeks for 4 doses, followed by maintenance doses of both single-agent nivolumab and the combination. Objective responses occurred in 40% of the patients, although 53% developed grade 3 or 4 treatmentrelated adverse events. 38 These promising data led to 2 randomized trials that addressed the role of combined nivolumab and ipilimumab versus ipilimumab monotherapy. In the phase II CheckMate-069 trial, treatment-naive patients (n = 142) with advanced melanoma were randomized 2:1 to receive either the combination of nivolumab 1 mg/kg and ipilimumab 3 mg/kg (n = 95) or ipilimumab 3 mg/kg plus placebo (n = 47) every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg or placebo every 2 weeks until disease progression or unacceptable toxicity. 17 The primary endpoint was the ORR among patients with BRAF wild-type tumors and was significantly improved in patients treated with the combination: 61% versus 11% (P < 0.001), with 22% of the patients achieving a complete response and a median duration of response not reached. In an updated analysis after a median follow-up of 24.5 months and including the overall study population, 2-year OS rates were 63.8% in the combination group and 53.6% in the ipilimumab plus placebo group; median OS had not been reached in either group (HR, 0.74; 95% CI, 0.43-1.26; P = 0.26). Updated ORRs for combination and ipilimumab monotherapy were 59% and 11%, respectively (61% and 11% in BRAF wild-type patients, respectively). Among patients harboring BRAF wild-type tumors, the 2-year OS rate with nivolumab/ ipilimumab was 69%, and it was 53% with ipilimumab plus placebo. 36 Notably, after progressive disease, many patients in the ipilimumab plus placebo group initially were able to receive nivolumab. Likely this accounted for the favorable OS in the ipilimumab plus placebo group.
The CheckMate-069 study, however, was not powered or conceived to test the hypothesis that the combination of ipilimumab and nivolumab would result in an OS improvement, and this was addressed in the phase III CheckMate-067 trial. In this randomized, 3-arm trial, patients were assigned 1:1:1 to nivolumab 1 mg/kg every 3 weeks plus ipilimumab 3 mg/kg every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg every 2 weeks, single-agent nivolumab 3 mg/kg every 2 weeks, or single-agent ipilimumab 3 mg/kg every 3 weeks for 4 doses. 18 The study was designed to allow for a direct comparison between any nivolumab-containing arms and ipilimumab with PFS and OS as coprimary endpoints; the comparison between ipilimumab/nivolumab versus singleagent nivolumab, however, was exploratory. Results were updated with a median follow-up of approximately 30 months in both nivolumab-containing arms. 37 Objective response rates were 58.9% for ipilimumab plus nivolumab (including 17.2% of complete responses), 44.6% for single-agent nivolumab alone, and 19% for single-agent ipilimumab. Updated PFS analyses suggested a 58% relative reduction in the risk of disease progression in favor of the combination when compared with ipilimumab alone (median PFS, 11.7 vs. 2.9 months; HR, 0.42; 95% CI, 0.34-0.51; P < 0.001); median PFS was also prolonged with nivolumab monotherapy compared with ipilimumab alone (median PFS, 6.9 vs. 2.9 months; HR, 0.54; 95% CI, 0.45-0.66; P < 0.001).
In an exploratory analysis, median PFS was superior with the combination versus nivolumab monotherapy (HR, 0.76; 95% CI, 0.62-0.94). Although median OS had not been reached in neither nivolumab-containing arm, 2-year OS rates were 64% for ipilimumab and nivolumab and 59% for single-agent nivolumab, a difference that was not statistically significant at this point in this exploratory analysis (HR, 0.88; 95% CI, 0.69-1.12), and 45% for single-agent ipilimumab (P < 0.0001 for both comparisons with ipilimumab and nivolumab [HR, 0.55] or single-agent nivolumab [HR, 0.63]). 37 It is important to emphasize that, although the combination of nivolumab and ipilimumab indeed resulted in more pronounced objective responses and prolonged PFS compared with ipilimumab, evidence is lacking to support the combination significantly improving OS over nivolumab alone. Also, combined checkpoint blockade is clearly not suitable for all patients because of the increased risk of significant and rarely life-threatening treatmentrelated adverse events. In CheckMate-069, treatment-related grade 3 or 4 adverse event occurred in 54% of the patients treated with ipilimumab and nivolumab, resulting in treatment discontinuation in 28 (30%) of 94 patients in the combination group and 4 (9%) of 46 patients in the ipilimumab group. 36 In the updated safety analysis of CheckMate-067, 58.5% of the patients treated with the combination developed grade 3 or 4 adverse event versus 20.8% with singe-agent nivolumab. 37 A summary of treatment-related adverse events is described in Table 2 . Despite the high rate of treatment discontinuation of combination immunotherapy, outcomes among this group of patients nevertheless seem favorable. 39 In an attempt to minimize the incidence of adverse events, a combination regimen consisting of ipilimumab at a reduced dose and pembrolizumab at the standard dose was investigated in the KEYNOTE-029 study. In this open-label, phase I trial, patients (n = 153) were treated with "low-dose" ipilimumab (1 mg/kg given every 3 weeks for 4 doses) combined with standard dose pembrolizumab (2 mg/kg given every 3 weeks). 40 Grade 3 or 4 treatment-related adverse events and discontinuation due to toxicities occurred in 45% and 14% of the patients, respectively; there were no treatment-related deaths. Sixty-one percent of the patients achieved an objective response, and 1-year OS rate was 89%. One important point to discuss, however, is that ipilimumab results in antitumor effects related to OS in a dose-dependent manner, at least when used as single agent. In a recently published randomized trial, ipilimumab 10 mg/kg was associated with an improvement in OS compared with ipilimumab 3 mg/kg (median OS, 15.7 vs. 11.5 months; HR, 0.84; 95% CI, 0.70-0.99; P = 0.04), with a 3-year OS rate of 31.2% versus 23.2%, at a cost of increased toxicity (grades 3-5 treatment-related toxicities of 34.3% vs. 18.5% with ipilimumab 3 mg/kg). 41 Therefore, larger randomized trials and extended follow-up are required to understand the efficacy of combination regimens involving reduced different doses of ipilimumab on OS.
Efficacy of Anti-PD-1 Agents in Patients With Central Nervous System Metastases
The presence of central nervous system involvement has typically defined a subset of patients with an ominous prognosis. Benefit from ipilimumab in this setting was usually limited to a small percentage of patients and short-lived. 42 Recent evidence, however, suggests the treatment of patients with brain metastases is also being positively affected by the incorporation of anti-PD-1 agents and combined immunotherapy approaches.
In a randomized phase II study, nivolumab resulted in intracranial ORR of 20% of asymptomatic patients and with no prior central nervous system-directed therapies, increasing to an intracranial ORR of 42% with the combination of ipilimumab and nivolumab for patients with the same characteristics, although PFS intervals were limited: intracranial 6-month PFS rates of 28% and 46%, respectively. 43 These data are consistent with efficacy of pembrolizumab for patients with melanoma brain metastases in a single-arm, phase II study conducted in a small group 
Bedside Questions Unanswered by Current Clinical Trials and Future Directions
Despite significant advances introduced by anti-PD-1 therapy, a broad number of questions applicable to clinical practice continue to emerge. One question relates to the optimal duration of treatment with anti-PD-1 agents. In KEYNOTE-001, among 61 patients with complete responses who stopped pembrolizumab after a median time on treatment of 23 months and additional 10 months of follow-up off treatment, 97% of the responses were maintained. 24 These are promising results, but they must be interpreted with caution because of the limited follow-up. Additional data on duration of therapy come from the KEYNOTE-006 trial, where patients received pembrolizumab for up to 24 months. Those with a complete response treated for at least 6 months could discontinue therapy after receiving at least 2 doses beyond the determination of complete response. 34 Data on patients treated in KEYNOTE-006 who completed protocol-specified time on treatment and discontinued pembrolizumab (including those with a variety of disease outcomes) were recently presented. Among these patients who discontinued pembrolizumab at 2 years, 91% remained progression-free after a median follow-up of 9.7 months. Taken together, these data allow one to hypothesize that shorter treatment duration may be equally beneficial for select patients, and this needs to be further investigated in prospective, randomized discontinuation trials. 34 In addition, clinically validated biomarkers remain an unmet need. Since early-phase clinical development, correlations between expression of PD-L1 by immunohistochemistry and response to treatment have been demonstrated. 19 Nevertheless, the determination of PD-L1 involves a series of caveats, including different antibodies used for immunohistochemical staining across distinct clinical trials, lack of standardization or definition of cutoff value for positivity/negativity, and intrapatient-intertumoral heterogeneity. More importantly, expression of PD-L1 in melanoma samples has never been shown to be a biomarker ready for treatment decision making among those candidates for singleagent anti-PD-1 therapy; even patients classified as PD-L1 negative may derive benefit from therapy (Table 3) . Subgroup analyses from the CheckMate-067 trial suggest, however, that the expression of PD-L1 may be relevant to PFS differences between patients treated with ipilimumab and nivolumab compared with nivolumab alone, but patients have a higher response rate with the combination regardless of their PD-L1 status, making clinical application of this biomarker difficult. 37 Hopefully, in the future, a better understanding of potentially useful biomarkers (neoantigen load, commensal bacteria, gene expression profiles associated with a proinflammatory microenvironment, quality of the immune infiltrate, etc) will allow for a tailored approach for those who are candidates for immunotherapy. Perhaps equally relevant is the importance of biomarkers in the clinical development of a growing number of potential combinations involving anti-PD-1 agents. The association of anti-PD-1 agents with inhibitors of checkpoints beyond CTLA-4 is being extensively evaluated, and the feasibility of combinations with ICOS, GITR and CD27 agonists, and inhibitory anti-LAG3 antibodies has been demonstrated, accompanied by promising antitumor activity. [47] [48] [49] [50] Targeting different steps involved in the composition of an effective immune response also offers growing opportunities; among these targets, indoleamine 2,3-dioxygenase, a cytosolic enzyme involved in immunosuppressive effects, down-regulation of effector T cells, and immune tolerance mechanisms, surfaces as a potential candidate. 51 Indoleamine 2,3-dioxygenase inhibitors, including epacadostat and indoximod, yielded exciting results and apparently a favorable toxicity profile when used in combination with ipilimumab and pembrolizumab in early-phase clinical trials. [52] [53] [54] [55] [56] [57] Also, for the meaningful proportion of patients with activating BRAF mutations, therapeutic options have been largely multiplied following the incorporation of BRAF and MEK inhibitors, and the best treatment sequence/algorithm for these patients who are also candidates for immune-checkpoint blockade is being clarified in ongoing randomized clinical trials. However, the convergence of immunotherapy and targeted therapy is also of clinical interest. As an example, significant activity was demonstrated in patients with tumors harboring BRAF V600 mutations treated with the triplet combination of a BRAF + MEK inhibitors and the anti-PD-L1 agent, atezolizumab. 58 
CONCLUSIONS
While single-agent anti-PD-1 remains a standard of care for a large proportion of individuals who are candidates for immunotherapy, select patients may benefit from combined PD-1 and CTLA-4 blockade, and ongoing clinical trials are expanding combinations of treatment possibilities. As management algorithms continue to evolve, the incorporation of reliable, validated biomarkers and the rational investigation of combinations are crucial for the enhancement of the benefits that derived from the incorporation of immunotherapy for patients with advanced melanoma. 
